Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03ETN
|
|||
| Drug Name |
PMID27828716-Compound-18
|
|||
| Drug Type |
Small molecular drug
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H16ClN5
|
|||
| Canonical SMILES |
CC1=CC(=NN1)NC2=NC(=NC(=C2C)C)C3=CC=CC=C3Cl
|
|||
| InChI |
1S/C16H16ClN5/c1-9-8-14(22-21-9)19-15-10(2)11(3)18-16(20-15)12-6-4-5-7-13(12)17/h4-8H,1-3H3,(H2,18,19,20,21,22)
|
|||
| InChIKey |
ONBXAMQNBSFIQS-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glycogen synthase kinase-3 alpha (GSK-3A) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Glycogen synthase kinase-3 alpha (GSK-3A) | Target's Patent Info | [1] | |
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Insulin/IGF pathway-protein kinase B signaling cascade | ||||
| PDGF signaling pathway | ||||
| Ras Pathway | ||||
| Pathway Interaction Database | Degradation of beta catenin | |||
| Canonical Wnt signaling pathway | ||||
| FOXM1 transcription factor network | ||||
| Class I PI3K signaling events mediated by Akt | ||||
| Reactome | AKT phosphorylates targets in the cytosol | |||
| XBP1(S) activates chaperone genes | ||||
| Constitutive Signaling by AKT1 E17K in Cancer | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.